-+ 0.00%
-+ 0.00%
-+ 0.00%

AMBROS THERAPEUTICS ANNOUNCES PLANNED INTERIM ANALYSIS OF PHASE 3 CLINICAL TRIAL FOLLOWING FDA FEEDBACK

Reuters·10/26/2026 12:35:19

Please log in to view news